American Cancer Society Asks $5.69 Billion for NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

WASHINGTON-The American Cancer Society (ACS) has offered a 13-point legislative agenda for 2002. The agenda backs President Bush’s request that Congress provide the National Institutes of Health $27.3 billion for fiscal year (FY) 2003, thus completing the doubling of the agency’s budget over 5 years.

WASHINGTON—The American Cancer Society (ACS) has offered a 13-point legislative agenda for 2002. The agenda backs President Bush’s request that Congress provide the National Institutes of Health $27.3 billion for fiscal year (FY) 2003, thus completing the doubling of the agency’s budget over 5 years.

ACS also wants the House and Senate to appropriate $5.69 billion for the National Cancer Institute, an increase of almost 36% above the $4.725 billion sought by Mr. Bush for FY2003, which begins on Oct. 1.

ACS also advocates $199.6 million (+24.4%) for the National Center for Minority Health and Health Disparities and $5 billion for the Centers for Disease Control and Prevention (CDC). The CDC figure represents an increase of $700 million (+16.2%), of which $1 billion (+33.7%) would fund the agency’s chronic disease prevention and health promotion program. ACS seeks $348 million to fund CDC’s cancer prevention and control efforts, an increase of 29.4% above the FY2002 budget

The ACS also urges Congress to provide $130 million (+28.7%) to fund the National Tobacco Control Plan/Office of Smoking and Health; $60 million (+118.1) for nutrition and physical activity; and $50 million (+32.3%) for CDC’s race initiatives.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Related Content